Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Ocugen, Inc.

An announcement from Ocugen ( ($OCGN) ) is now available. On January 20, 2026, Ocugen, Inc. entered into an underwriting agreement with Oppenheimer...

Ocugen Announces $22.5 Million Public Stock Offering

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Kymera Therapeutics (KYMR – Research Report), GeneDx...

Analysts Are Bullish on These Healthcare Stocks: Kymera Therapeutics (KYMR), GeneDx Holdings (WGS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Regeneron (REGN – Research Report) and Ocugen (OCGN ...

Analysts’ Top Healthcare Picks: Regeneron (REGN), Ocugen (OCGN)

Analysts see strong upside potential in these three small-cap stocks.


Current Quarter	$-0.06	Next Quarter	$-0.06
Current Year	$-0.23	Next Year	$-0.26
QoQ Growth	+0.0%	YoY Growth	-13.0%
3Y EPS CAGR	+12.6%	Target Price	$9.00
Consensus	Buy	Upside	+502.0%

Current Quarter Rev	N/A	Next Quarter Rev	N/A
Revenue Growth	N/A	YoY Growth	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	OCGN	$1.50	+4.55%	3.31M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	OCGN	$1.50	+4.5%	3.31M
3
4
5
6

OCGN

OCGN

EPS Estimates Overview

EPS Historical Trend (5 Years)

Quarterly EPS Estimates

Revenue Analysis

Get Ocugen, Inc. Data in Excel

Get Ocugen, Inc. Data in Excel